✦ LIBER ✦

Lapatinib plus paclitaxel versus paclitaxel alone for first line metastatic breast cancer (MBC) in ErbB2+ patients -Quality of Life (QOL) results

✍ Scribed by Y. Wu; A. Segreti; D. Cella; A. DiLeo; M. Amonkar; M. Koehler; M. Arbushites; M. Walker

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lapatinib plus capecitabine versus capec

✍ X. Zhou; A. Segreti; D. Cella; D. Cameron; C. Geyer; M. Amonkar; S. Stein; M. Wa 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Lapatinib plus capecitabine versus capec

✍ Xiaolei Zhou; David Cella; David Cameron; Mayur M. Amonkar; Anthony Segreti; Ste 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 534 KB

2097 ORAL Biomarker analysis of lapatini

✍ R.S. Finn; M.F. Press; J. Dering; H. Gomez; Z. Aziz; M. Arbushites; M. Koehler; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Quality-of-life and quality-adjusted sur

✍ Sherrill, Beth; Di Leo, Angelo; Amonkar, Mayur M.; Wu, Yun; Zvirbule, Zanete; Az 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 386 KB

Survival-adjusted health-related quality

✍ David Cella; Molin Wang; Lynne Wagner; Kathy Miller 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 241 KB

Capecitabine plus paclitaxel versus epir

✍ Hans-Joachim Lück, Andreas Du Bois, Sibylle Loibl, Iris Schrader, Jens Huober, V 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 279 KB